EGM REVELATIONS

From the EGM:

DARRT.  Treating late-stage patients who have failed every therapy has massive implications.  For instance:

• For as long as cancer remains unconquered, nearly every cancer patient will get to the stage that nothing works for them;
• A drug that improves the lives of end-stage patients, especially if it works across a range of cancers, would have a very large number of potential customers;
• The control arm patients in DARRT-2 will receive radiation alone, which will do nothing for them;
• If Veyonda replicates DARRT-1 results in its registration trial, it will become a blockbuster drug.

IONIC.  Veyonda has shown that it can cause abscopal responses in cancer patients, providing proof that can selectively transform COLD cells into HOT cells.

• The IONIC program will combine Veyonda with a check-point inhibitor
• If such a combination is effective, combination sales could reach $150 Billion per year
• Noxopharm would receive a fair percentage of any increased sales

VEYONDA MOA.  The Hudson Institute has discovered that Veyonda only interacts with systems that have gone rogue:

• In cancer, the abnormality is a supressed immune system.  Veyonda restores this function to normal by activating it.
• In septic shock, the abnormality is an over-active immune system.  Veyonda restores this function to normal by reducing it.
• The drug appears to have no harmful effect on normal cells.

COVID/SEPTIC SHOCK.  It is well known that about 20% of all human deaths are attributable to Septic Shock, and that the cause is an excessively high immune/inflammation response to infection, but it took an unexpected discovery by the Hudson Institute to make the STING connection:

• STING is the main cause of the cytokine storm implicated in Septic Shock deaths
• Hudson discovered that Veyonda selectively inhibited STING associated with cytokine storms
• And then scientists discovered that cytokine storms were the main cause of COVID deaths
• So Noxopharm is going to see whether Veyonda is safe to use in COVID patients
• And if it is, whether it can improve the status of COVID patients
• And if it is both safe and effective against COVID, then use Veyonda to treat Septic Shock

Each of the Noxopharm programs has blockbuster potential.  Hopefully Big Pharma will see something it likes.